237 related articles for article (PubMed ID: 24738920)
1. IL-10 function, regulation, and in bacterial keratitis.
Hazlett LD; Jiang X; McClellan SA
J Ocul Pharmacol Ther; 2014 Jun; 30(5):373-80. PubMed ID: 24738920
[TBL] [Abstract][Full Text] [Related]
2. Regulation and functions of the IL-10 family of cytokines in inflammation and disease.
Ouyang W; Rutz S; Crellin NK; Valdez PA; Hymowitz SG
Annu Rev Immunol; 2011; 29():71-109. PubMed ID: 21166540
[TBL] [Abstract][Full Text] [Related]
3. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.
Mannis MJ
Trans Am Ophthalmol Soc; 2002; 100():243-71. PubMed ID: 12545697
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 17 regulates Mer tyrosine kinase-positive cells in Pseudomonas aeruginosa keratitis.
Li C; McClellan SA; Barrett R; Hazlett LD
Invest Ophthalmol Vis Sci; 2014 Oct; 55(10):6886-900. PubMed ID: 25298414
[TBL] [Abstract][Full Text] [Related]
5. The Regulating Role of SB216763 in Pseudomonas aeruginosa Keratitis.
Chen K; Fu Q; Ye C; Zhan X; Lu J; Du M; Feng Y; Liang P; Wang W
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625371
[TBL] [Abstract][Full Text] [Related]
6. Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis.
Chew FL; Soong TK; Shin HC; Samsudin A; Visvaraja S
J Ocul Pharmacol Ther; 2010 Apr; 26(2):219-22. PubMed ID: 20415627
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Li SA; Liu J; Xiang Y; Wang YJ; Lee WH; Zhang Y
Antimicrob Agents Chemother; 2014 Jun; 58(6):3144-50. PubMed ID: 24637683
[TBL] [Abstract][Full Text] [Related]
8. Thrombomodulin Protects Against Bacterial Keratitis, Is Anti-Inflammatory, but Not Angiogenic.
McClellan SA; Ekanayaka SA; Li C; Jiang X; Barrett RP; Hazlett LD
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8091-100. PubMed ID: 26720461
[TBL] [Abstract][Full Text] [Related]
9. Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.
Clemens LE; Jaynes J; Lim E; Kolar SS; Reins RY; Baidouri H; Hanlon S; McDermott AM; Woodburn KW
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6273-6281. PubMed ID: 29242901
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhizin Reduces HMGB1 and Bacterial Load in Pseudomonas aeruginosa Keratitis.
Ekanayaka SA; McClellan SA; Barrett RP; Kharotia S; Hazlett LD
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5799-5809. PubMed ID: 27792814
[TBL] [Abstract][Full Text] [Related]
11. ISG15 Acts as a Mediator of Innate Immune Response to Pseudomonas aeruginosa Infection in C57BL/6J Mouse Corneas.
Gao N; Me R; Dai C; Yu FX
Invest Ophthalmol Vis Sci; 2020 May; 61(5):26. PubMed ID: 32416603
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic considerations in the treatment of bacterial keratitis.
Callegan MC; O'Callaghan RJ; Hill JM
Clin Pharmacokinet; 1994 Aug; 27(2):129-49. PubMed ID: 7955776
[TBL] [Abstract][Full Text] [Related]
13. A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.
Chojnacki M; Philbrick A; Scherzi T; Pecora N; Dunman PM; Wozniak RAF
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332071
[TBL] [Abstract][Full Text] [Related]
14. Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis.
Okurowska K; Roy S; Thokala P; Partridge L; Garg P; MacNeil S; Monk PN; Karunakaran E
J Vis Exp; 2020 May; (159):. PubMed ID: 32478743
[TBL] [Abstract][Full Text] [Related]
15. Oxygen Self-Supplying Nanotherapeutic for Mitigation of Tissue Hypoxia and Enhanced Photodynamic Therapy of Bacterial Keratitis.
Bai Y; Hu Y; Gao Y; Wei X; Li J; Zhang Y; Wu Z; Zhang X
ACS Appl Mater Interfaces; 2021 Jul; 13(29):33790-33801. PubMed ID: 34254513
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Pseudomonas keratitis in humans.
Hessburg PC
Am J Ophthalmol; 1966 May; 61(5 Pt 1):896-903. PubMed ID: 16874993
[TBL] [Abstract][Full Text] [Related]
17. [Bacterial keratites].
Robert PY; Adenis JP
J Fr Ophtalmol; 1999 Dec; 22(10):1104-9. PubMed ID: 10617850
[No Abstract] [Full Text] [Related]
18. Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Chojnacki M; Philbrick A; Wucher B; Reed JN; Tomaras A; Dunman PM; Wozniak RAF
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30420484
[No Abstract] [Full Text] [Related]
19. Corneal response to Pseudomonas aeruginosa infection.
Hazlett LD
Prog Retin Eye Res; 2004 Jan; 23(1):1-30. PubMed ID: 14766315
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of VIP as Treatment for Bacteria-Induced Keratitis Against Multiple Pseudomonas aeruginosa Strains.
Carion TW; McWhirter CR; Grewal DK; Berger EA
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6932-40. PubMed ID: 26513498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
